Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares are down during Tuesday’s premarket session as the company announced a definitive agreement to acquire Corstasis Therapeutics.
This news comes as broader markets experienced declines, with major indices like the S&P 500 and Nasdaq both closing lower on the previous trading day.
Esperion has entered into an agreement to acquire Corstasis, which developed Enbumyst, the first FDA-approved nasal spray diuretic for treating edema associated with congestive heart failure. Enbumyst brings “meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy”.
Deal Terms and Financing Structure
The deal includes an upfront cash payment of $75 million, along with potential royalties and milestone payments that could total up to $180 million.
Esperion said it will finance the acquisition through its existing credit facilities and royalty monetization of its Japanese royalties with funds managed by Athyrium Capital Management and HealthCare Royalty.
As of September 30, 2025, cash and cash equivalents totaled $92.4 million. The transaction is expected to close in the second quarter of 2026.
Strategic Rationale and Market Opportunity
The acquisition aims to leverage Esperion’s established cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion in the U.S. alone.
This strategic move is expected to enhance Esperion’s product portfolio and drive double-digit revenue growth as it integrates Enbumyst into its operations.
Chief Executive Officer Sheldon Koenig said, “We expect that by integrating Enbumyst into our proven commercial platform, we will drive sustained double-digit growth, strengthen our leadership in cardiovascular care, and create durable value for all of our stakeholders – from patients and providers to employees and shareholders.”
Technical Analysis
Currently, the stock is trading 5.5% below its 20-day simple moving average (SMA) and 12.3% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased significantly, and they are currently positioned closer to their 52-week lows than highs, reflecting ongoing challenges for the company.
The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum for Esperion at this time.
- Key Resistance: $4.00
- Key Support: $2.50
Earnings & Analyst Outlook
The countdown is on: the company is set to report earnings on March 10, 2026.
- EPS Estimate: 26 cents (Up from Loss of 11 cents)
- Revenue Estimate: $163.31 million (Up from $69.11 million)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $6.31. Recent analyst moves include:
- Piper Sandler: Initiated with Overweight (Target $9.00) (Nov. 25, 2025)
- HC Wainwright & Co.: Buy (Maintains Target to $16.00) (Sep. 19, 2025)
ESPR Price Action: Esperion Therapeutics shares were down 5.40% at $3.09 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
